Table 4.
Pre-ART BMI Subgroup | IL-6, log10 pg/mL | sTNF-RII, log10 pg/mL | CXCL-10, log10 pg/mL | sCD163, log10 ng/mL | hsCRP, log10 μg/mL |
---|---|---|---|---|---|
Normal weight | 0.26 (.17 to .35) | 0.12 (.07 to .16) | 0.19 (.11 to .27) | 0.08 (.02 to .14) | 0.32 (.16 to .48) |
Overweight | 0.04 (−.06 to .13) | 0.01 (−.05 to .06) | 0.07 (−.02 to .15) | 0.05 (−.02 to .11) | 0.00 (−.32 to .03) |
Obese | −0.08 (−.20 to .05) | −0.06 (−.13 to .01) | 0.05 (−.06 to .16) | −0.05 (−.13 to .03) | −0.07 (−.29 to .16) |
Models adjusted for sex, age (by decade), race/ethnicity, pre-ART viral load and CD4 cell count, and ART assignment. Bold text indicates a statistically significant comparison.
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; sTNF-RII, soluble TNF-α receptor II.